Journal of Osteoporosis is a leading open-access journal dedicated to the investigation and dissemination of research in the field of osteoporosis and related bone disorders. Published by HINDAWI LTD, the journal has been fostering academic discourse since 2010, ensuring that critical findings are accessible to researchers, clinicians, and policy-makers alike. With an ISSN of 2090-8059 and an E-ISSN of 2042-0064, it serves as a significant platform for advancing knowledge in Endocrinology, Diabetes, and Metabolism, currently holding Q4 and Q3 categorizations in respective quartiles as of 2023. The journal, which publishes annually and is based in the United States, plays a crucial role in documenting the evolving understanding of bone health, contributing to improved clinical practices and patient outcomes. As it converges insights from diverse fields, it is an essential resource for researchers aiming to impact the future of osteoporosis management and treatment.

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

JOURNAL OF BONE AND MINERAL METABOLISM, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing the field of bone and mineral research since its establishment in 1988. With ISSN 0914-8779 and E-ISSN 1435-5604, this esteemed journal offers a platform for high-quality research that intersects Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine, and related disciplines. Recognized for its rigorous standards, it holds a commendable Q2 ranking in multiple categories, reflecting its broad influence and relevance in contemporary medical research. Researchers and practitioners alike benefit from its evidence-based articles and insights, which contribute significantly to our understanding of metabolic bone diseases and mineral homeostasis. Although not an open-access journal, it still provides essential information and advancements crucial for professionals and scholars dedicated to improving clinical outcomes and enhancing patient care in these vital areas. To learn more, please explore the journal's archives and latest publications.

Bone Research is a premier open-access journal published by SpringerNature, dedicated to advancing the understanding of bone biology and its related disciplines. Established in 2013 and based in the United Kingdom, this journal has quickly ascended to the forefront of scientific inquiry, evidenced by its esteemed Q1 rankings in 2023 across multiple categories including Endocrinology, Diabetes and Metabolism, Histology, and Physiology. With a commendable impact reflected in its Scopus ranks—positioned #2 in Histology, #9 in Endocrinology, and #8 in Physiology—Bone Research serves as a vital platform for researchers, healthcare professionals, and students alike to share and access cutting-edge findings. Since adopting an open-access model in 2014, the journal has empowered an expansive audience by facilitating immediate availability of high-quality research. This aligns with its commitment to foster innovation and collaboration within the fields it encompasses. As it converges its efforts from 2013 to 2024, Bone Research remains a critical resource for those looking to deepen their investigation into bone health and diseases, ensuring its place as a leader in promoting scientific excellence.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

JBMR Plus, published by Wiley, is a leading open-access journal dedicated to advancing the fields of Endocrinology, Diabetes and Metabolism as well as Orthopedics and Sports Medicine. Since its inception in 2017, JBMR Plus has rapidly gained recognition within the scientific community, achieving prestigious Q1 rankings in both categories as of 2023. This esteemed journal hosts cutting-edge research, providing a platform for innovative studies that explore the intersections of bone health, metabolism, and athletic performance. With a robust Scopus ranking, where it stands in the top percentiles for its specialties, JBMR Plus aims to disseminate knowledge and foster collaborations among researchers, healthcare professionals, and students dedicated to improving patient outcomes. Researchers worldwide can access its content freely, ensuring that crucial findings reach a diverse audience, contributing significantly to the discourse in these vital medical fields.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.